RCUS - CIK 0001724521
Arcus Biosciences, Inc. (RCUS) reported net income of -$353.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$353.00M | -24.7% |
| FY 2024 | -$283.00M | +7.8% |
| FY 2023 | -$307.00M | -15.0% |
| FY 2022 | -$267.00M | -603.8% |
| FY 2021 | $53.00M | +143.1% |
| FY 2020 | -$123.00M | -45.2% |
| FY 2019 | -$84.71M | -70.8% |
| FY 2018 | -$49.59M | +6.6% |
| FY 2017 |
Arcus Biosciences, Inc. (RCUS) reported net income of -$353.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2016 and fiscal 2025, Arcus Biosciences, Inc.'s net income declined from -$17.97M to -$353.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$53.08M |
| -195.4% |
| FY 2016 | -$17.97M | - |